Prevalence of primary sclerosing cholangitis (PSC) in Iranian adult patients with inflammatory bowel disease (IBD) or liver disorders: systematic review and meta-analysis
Gastroenterology and Hepatology from Bed to Bench,
Vol. 18 No. 1 (2025),
4 January 2025
https://doi.org/10.22037/ghfbb.v18i1.3046
Abstract
Aim: To evaluate the prevalence of primary sclerosing cholangitis (PSC) among Iranian adult patients with inflammatory bowel disease (IBD) or liver disorders.
Background: PSC is a rare and chronic liver disease characterized by inflammation, fibrosis, and intra- and/or extrahepatic bile duct structure.
Methods: A systematic review and meta-analysis was conducted. The Web of Science, Scopus, Pubmed, Embase, Google Scholar, and local databases, including the IranDoc, IranMedex, SID, and MagIran databases, were searched for studies published before 6th February 2023 for the prevalence of PSC among Iranian adults.
Results: In total, 22 articles involving 19,747 Iranian participants were included in this meta-analysis. The overall pooled prevalence of PSC was 8% (95% CI: 5%–12%). Additionally, the prevalence of PSC stratified by gender was calculated based on four studies (n = 1402). The pooled prevalence of PSC was estimated to be 20% (95% CI: 11–31%) in males and 12% (95% CI: 3–38%) in females. The pooled prevalence of PSC was 6% (95% CI: 4–9%) in patients with IBD and 14% (95% CI: 8–23%) in patients with liver transplantation (LT).
Conclusion: The pooled prevalence of PSC was 8% in Iranian adults, and the prevalence was greater in males than in females.
- primary biliary cholangitis (PBC)
- prevalence
- systematic review
- Iran
- meta-analysis
How to Cite
References
Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Br Med Bull 2015;114:53-64.
de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012;32:441-8.
Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011;9:1092-7.
Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004;53:865-70.
Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-5.
Mertz A, Nguyen NA, Katsanos KH, Kwok RM. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol 2019;32:124-133.
de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 2015;21:1956-71.
Heikius B, Niemelä S, Lehtola J, Karttunen T, Lähde S. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol 1997;32:153-61.
Huber W, Kranzmayr M, Schultheiss C, Reindl W, Krug A, Saugel B, et al. Indocyanine green plasma disappearance rate for assessment of liver function: re-evaluation of normal ranges and impact of biometric data. Crit Care 2013;17:178.
Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC phenotypes of PSC-IBD. Curr Gastroenterol Rep 2018;20:16.
Krones E, Marschall HU, Fickert P. Future medical treatment of PSC. Curr Hepatology Rep 2019;18:96–106.
Trivedi PJ, Bowlus CL, Yimam KK, Razavi H, Estes C. Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies. Clin Gastroenterol Hepatol 2022;20:1687-1700.
Barner-Rasmussen N, Pukkala E, Jussila A, Färkkilä M. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scand J Gastroenterol 2020;55:74-81.
Bakhshi Z, Hilscher MB, Gores GJ, Harmsen WS, Viehman JK, LaRusso NF, et al. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. J Gastroenterol 2020;55:523-532.
Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan JY. Clinical profile of primary sclerosing cholangitis in Singapore. J Gastroenterol Hepatol 2002;17:908-13.
Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002;97:2402-7.
Beheshti Maal A, Shahrbaf MA, Sadri B, Hossein-Khannazer N, Mansournia MA, Vosough M. Prevalence of hepatobiliary manifestations in inflammatory bowel disease: a grade assessed systematic review and meta-analysis of more than 1.7 million patients. J Crohns Colitis 2024;18:360-374.
Singh A, Midha V, Narang V, Kedia S, Mahajan R, Dhoble P, et al. Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India. Intest Res 2023;21:452-459.
Gudnason HO, Kristinsson JO, Bergmann OM, Olafsson S, Jonasson JG, Bjornsson ES. Primary sclerosing cholangitis in Iceland 1992-2012. Laeknabladid 2019;105:371-376.
Takikawa H, Takamori Y, Tanaka A, Kurihara H, Nakanuma Y. Analysis of 388 cases of primary sclerosing cholangitis in Japan; Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004;29:153-159.
Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6.
Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004;126:1929-30.
Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007;102:1042-9.
Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology 2021;161:1865-1877.
Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152:1975-1984.
Lamba M, Ngu JH, Stedman CAM. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis. Clin Gastroenterol Hepatol 2021;19:573-579.
Lindkvist B, Benito de Valle M, Gullberg B, Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010;52:571-7.
Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL. Characteristics and outcomes reported by patients with primary sclerosing cholangitis through an online registry. Clin Gastroenterol Hepatol 2019;17:1372-1378.
Trivedi PJ, Crothers H, Mytton J, Bosch S, Iqbal T, Ferguson J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology 2020;159:915-928.
Malek-Hosseini SA, Jafarian A, Nikeghbalian S, Poustchi H, Lankarani KB, Nasiri Toosi M, et al. Liver transplantation status in Iran: a multi-center report on the main transplant indicators and survival rates. Arch Iran Med 2018;21:275-282.
Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol 2005;20:1691-5.
Saberifiroozi M, Serati AR, Malekhosseini SA, Salahi H, Bahador A, Lankarani KB, et al. Analysis of patients listed for liver transplantation in Shiraz, Iran. Indian J Gastroenterol 2006;25:11-3.
Ganji A, Safavi M, Nouraie M, Nasseri Moghaddam S, Merat S, Vahedi H, et al. Digestive and liver diseases statistics in several referral centers in Tehran, 2000-2004. Govaresh 2006;11:33-38.
Dehghani SM, Derakhshan A, Taghavi SA, Gholami S, Jalaeian H, Malek-Hosseini SA. Prevalence and risk factors of renal dysfunction after liver transplant: a single-center experience. Exp Clin Transplant 2008;6:25-9.
Darakhshan F, Vali Khojeini E, Balaii H, Naderi N, Firouzi F, Farnood A, et al. Epidemiology of inflammatory bowel disease in Iran: a review of 803 cases. Gastroenterol Hepatol Bed Bench 2009;1.
Vahedi H, Merat S, Momtahen S, Olfati G, Kazzazi AS, Tabrizian T, et al. Epidemiologic characteristics of 500 patients with inflammatory bowel disease in Iran studied from 2004 through 2007. Arch Iran Med 2009;12:454-60.
Mirzaagha F, Azali SH, Islami F, Zamani F, Khalilipour E, Khatibian M, et al. Coeliac disease in autoimmune liver disease: a cross-sectional study and a systematic review. Dig Liver Dis 2010;42:620-3.
Yazdanbod A, Farzaneh E, Pourfarzi F, Azami A, Mostafazadeh B, Adiban V, et al. Epidemiologic profile and clinical characteristics of ulcerative colitis in northwest of Iran: a 10-year review. Trop Gastroenterol 2010;31:308-11.
Mohammad-Alizadeh AH, Ghobakhlou M, Shalmani HM, Zali MR. Cholangiocarcinoma: an-eight-year experience in a tertiary-center in Iran. Asian Pac J Cancer Prev 2012;13:5381-4.
Jafarshad R, Daryani N, Shekarriz R. Serum IgG4 levels in patients with ulcerative colitis, a predicting factor for primary sclerosing cholangitis? Govaresh 2013;18:100-105.
Khosravi Khorashad A, Khajedaluee M, Mokhtari Amirmajdi E, Bahari A, Farzanehfar MR, Ahadi M, et al. Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran. Gastroenterol Hepatol Bed Bench 2015;8:200-6.
Fattahi MR, Malek-Hosseini SA, Sivandzadeh GR, Safarpour AR, Bagheri Lankarani K, Taghavi AR, et al. Clinical course of ulcerative colitis after liver transplantation in patients with concomitant primary sclerosing cholangitis and ulcerative colitis. Inflamm Bowel Dis 2017;23:1160-1167.
Baghaei A, Emami MH, Adibi P, Tavakkoli H, Daghaghzadeh H, Tamizifar B, et al. Inflammatory bowel disease registry and monitoring: feasibility study and application (Isfahan Inflammatory Bowel Disease Surveillance Project). Int J Prev Med 2019;10:190.
Jeddi M, Aghasadeghi F, Ranjbar Omrani G, Malek-Hosseini SA, Lakarani KB. Incidence, risk factors, and follow-up of diabetes mellitus after liver transplant: a prospective study from Iran. Exp Clin Transplant 2021;19:928-934.
Nassiri Toosi M, Moazzami B, Jafarian A, Emami A, Azmodeh Ardalan F, Karimi M. Comparison of platelet count reduction in patients awaiting liver transplantation with and without primary sclerosing cholangitis: a cohort study. Arch Iran Med 2020;23:732-739.
Lankarani KB, Honarvar B, Zahedroozegar MH, Dehghan A, Rouhezamin MR, et al. Immunoglobulin G immunity to hepatitis a virus in liver transplant candidates: a serosurvey from Iran. Hepat Mon 2021;21:113001.
Bagheri Lankarani K, Honarvar B, Seif MA, Anushiravani A, Nikeghbalian S, Motazedian N, et al. Outcome of liver transplant patients with intraoperative-detected portal vein thrombosis: a retrospective cohort study in Shiraz, Iran. Exp Clin Transplant 2021;19:324-330.
- Abstract Viewed: 372 times
- PDF Downloaded: 227 times